---
document_datetime: 2023-09-21 17:51:32
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/clopidogrel-hcs-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: clopidogrel-hcs-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.6045976
conversion_datetime: 2025-12-19 04:38:18.074803
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Clopidogrel HCS

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0023              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 03/05/2018                          |                                             | SmPC and PL                      |           |
| IB/0022/G            | This was an application for a group of variations.                                                                                                                                                                                                           | 22/05/2017                          | 29/06/2017                                  | SmPC, Labelling and              |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by                                                                                                                                                                                                                                                                               |            |            | PL                    | C.I.2.a - Change the MAH   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------|
| IB/0021/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO | 18/12/2015 | 26/05/2016 | SmPC, Annex II and PL |                            |

<div style=\"page-break-after: always\"></div>

|           | the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0019    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 26/03/2015 | 16/06/2015 | Annex II               | Based on the review of available information, the CHMP is of the opinion that the quality, safety and efficacy of Clopidogrel HCS continues to be adequately and sufficiently demonstrated and considers that the benefit/risk profile of this medicinal product continues to be favourable. The product information has been updated to align with QRD templates. The CHMP recommends that the renewal be granted with unlimited validity. |
| IB/0020   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                 | 10/06/2015 | 26/05/2016 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0018/G | This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.d - Change in batch size (including batch size ranges) of AS or intermediate - More than 10-fold increase compared to the originally approved batch size | 04/02/2015 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                   | ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |             |                                   |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/820/2 01311 | Periodic Safety Update EU Single assessment - acetylsalicylic acid / clopidogrel, clopidogrel                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 10/07/2014 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0017/G         | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 24/04/2014 | 22/08/2014 | SmPC and PL |                                   |
| IB/0014           | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 09/04/2014 | n/a        |             |                                   |
| IAIN/0016         | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                      | 05/03/2014 | n/a        |             |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0013   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                         | 13/01/2014   | 22/08/2014   | SmPC and PL                      |               |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|---------------|
| IB/0012/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 21/10/2013   | 22/08/2014   | SmPC and PL                      | the MAH       |
| IB/0011/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following the same change for the reference                                                                                                                                   | 20/08/2013   | 22/08/2014   | SmPC, Annex II, Labelling and PL | assessment of |

<div style=\"page-break-after: always\"></div>

|           | product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |             |                       |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------|
| IB/0010/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size A.7 - Administrative change - Deletion of | 25/05/2012 | n/a        |             | manufacturing sites   |
| IB/0009   | B.II.a.3.z - Changes in the composition (excipients) of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                     | 26/03/2012 | 24/10/2012 | SmPC and PL |                       |
| IB/0007/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The                                                                                              | 24/10/2011 | n/a        |             | proposed manufacturer |

<div style=\"page-break-after: always\"></div>

|           | group as the currently approved                                                                                                                                                                                                                |            |     |                                  | pharmaceutical manufacturer   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------|-------------------------------|
| IA/0008   | C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV                                                                                                                                        | 28/09/2011 | n/a |                                  |                               |
| IB/0006   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                      | 08/09/2011 | n/a | SmPC                             |                               |
| IB/0004   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH | 26/07/2011 | n/a | SmPC and PL                      |                               |
| IA/0005   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                  | 19/07/2011 | n/a |                                  |                               |
| IB/0002   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH | 08/04/2011 | n/a | SmPC, Annex II, Labelling and PL |                               |
| IA/0003/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV to an existing pharmacovigilance                                                    | 05/04/2011 | n/a |                                  | C.I.9.h - Changes             |

<div style=\"page-break-after: always\"></div>

| system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same MAH   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|